{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:34Z","timestamp":1790717134434,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lpm.2026.104341","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:37:06Z","timestamp":1773531426000},"page":"104341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated review"],"prefix":"10.1016","volume":"55","author":[{"given":"Alberto","family":"Picca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.lpm.2026.104341_bib0001","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.lpm.2026.104341_bib0002","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"issue":"0","key":"10.1016\/j.lpm.2026.104341_bib0003","article-title":"Final, 10-year outcomes with Nivolumab plus Ipilimumab in advanced Melanoma","volume":"0","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.lpm.2026.104341_bib0004","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2026.104341_bib0005","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.lpm.2026.104341_bib0006","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in microsatellite-instability\u2013High metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2026.104341_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lpm.2026.104341_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non\u2013Small cell lung cancer (IMpower010): an open-label, randomized, phase III trial","author":"Felip","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.lpm.2026.104341_bib0009","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lpm.2026.104341_bib0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.lpm.2026.104341_bib0011","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-only Pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.lpm.2026.104341_bib0012","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with Immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2026.104341_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014A worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.lpm.2026.104341_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.lpm.2026.104341_bib0016","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.lpm.2026.104341_bib0017","doi-asserted-by":"crossref","first-page":"fcad169","DOI":"10.1093\/braincomms\/fcad169","article-title":"Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity","volume":"5","author":"Farina","year":"2023","journal-title":"Brain Commun"},{"issue":"6","key":"10.1016\/j.lpm.2026.104341_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200314","article-title":"Clinical course of neurologic adverse events associated with immune checkpoint inhibitors","volume":"11","author":"Rossi","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.lpm.2026.104341_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajem.2025.09.010","article-title":"Factors associated with immune-related adverse events in cancer patients treated with immunotherapy visiting the emergency department","volume":"99","author":"Naud","year":"2026","journal-title":"Am J Emerg Med"},{"issue":"16","key":"10.1016\/j.lpm.2026.104341_bib0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of Immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.lpm.2026.104341_bib0021","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2026.104341_bib0022","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0023","doi-asserted-by":"crossref","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"issue":"18","key":"10.1016\/j.lpm.2026.104341_bib0024","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10124","key":"10.1016\/j.lpm.2026.104341_bib0025","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.lpm.2026.104341_bib0027","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"j immunother cancer"},{"key":"10.1016\/j.lpm.2026.104341_bib0028","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health 13 Eur"},{"issue":"1","key":"10.1016\/j.lpm.2026.104341_bib0029","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.lpm.2026.104341_bib0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"10.1016\/j.lpm.2026.104341_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.lpm.2026.104341_bib0032","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","article-title":"Peripheral nervous system immune-related adverse events due to checkpoint inhibition","volume":"20","author":"O\u2019Hare","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.lpm.2026.104341_bib0033","first-page":"S74","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"10.1016\/j.lpm.2026.104341_bib0034","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.lpm.2026.104341_bib0035","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001034","article-title":"Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients","volume":"8","author":"Cuzzubbo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.lpm.2026.104341_bib0037","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","article-title":"A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2026.104341_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lpm.2026.104341_bib0039","article-title":"Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study","volume":"44","author":"Farina","year":"2024","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.lpm.2026.104341_bib0040","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2022.08.009","article-title":"Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study","volume":"175","author":"M\u00fcller-Jensen","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.lpm.2026.104341_bib0041","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/WCO.0000000000000676","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy","volume":"32","author":"Kunchok","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.lpm.2026.104341_bib0042","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1007\/s12311-024-01727-5","article-title":"Immune checkpoint inhibitor-related cerebellar toxicity: clinical features and comparison with paraneoplastic cerebellar ataxia","volume":"23","author":"Dentoni","year":"2024","journal-title":"Cerebellum"},{"issue":"3","key":"10.1016\/j.lpm.2026.104341_bib0043","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"6","key":"10.1016\/j.lpm.2026.104341_bib0044","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-interleukin-6 and janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"24","key":"10.1016\/j.lpm.2026.104341_bib0045","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.3390\/cancers17243935","article-title":"Specialist neurology involvement and impact in immune checkpoint inhibitor-related neurotoxicity: experience in a unified healthcare system","volume":"17","author":"Schroeder","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lpm.2026.104341_bib0046","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lpm.2026.104341_bib0047","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2026.104341_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.lpm.2026.104341_bib0049","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.lpm.2026.104341_bib0050","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.22.01602","article-title":"Neurological manifestations as a harbinger of myocarditis in patients treated with immune checkpoint inhibitors","volume":"41","author":"Rossi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.lpm.2026.104341_bib0051","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant Respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.lpm.2026.104341_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106026","article-title":"IL6 blockade: an effective approach in steroid-refractory immune checkpoint inhibitor-related neuropathies requiring ICI rechallenge-case report","volume":"11","author":"Baek","year":"2026","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.lpm.2026.104341_bib0053","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pr"},{"issue":"1","key":"10.1016\/j.lpm.2026.104341_bib0054","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-018-0471-2","article-title":"Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation","volume":"6","author":"Chang","year":"2018","journal-title":"j immunother cancer"},{"issue":"5","key":"10.1016\/j.lpm.2026.104341_bib0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"issue":"7756","key":"10.1016\/j.lpm.2026.104341_bib0056","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lpm.2026.104341_bib0057","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0058","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor\u2013induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0059","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-024-03901-4","article-title":"Anti-PD1-\/PDL1-induced chronic intestinal pseudo-obstruction: three cases treated with vedolizumab after corticosteroid failure with mixed results","volume":"74","author":"Zenatri","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0060","article-title":"Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis","volume":"10","author":"Nylander","year":"2024","journal-title":"Mult Scler J 13 Exp Transl Clin"},{"issue":"11","key":"10.1016\/j.lpm.2026.104341_bib0061","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210003","article-title":"Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications","volume":"103","author":"Quinn","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.lpm.2026.104341_bib0062","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200202","article-title":"Impact of immune checkpoint inhibitors on the course of multiple sclerosis","volume":"11","author":"Androdias","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"6","key":"10.1016\/j.lpm.2026.104341_bib0063","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.13727","article-title":"Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders","volume":"8","author":"Fletcher","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.lpm.2026.104341_bib0064","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","article-title":"Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study","volume":"22","author":"Fonseca","year":"2023","journal-title":"Lancet Neurol"},{"issue":"23","key":"10.1016\/j.lpm.2026.104341_bib0065","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2026.104341_bib0066","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.lpm.2026.104341_bib0067","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2026.104341_bib0068","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-009-0690-y","article-title":"Onconeural antibodies in sera from patients with various types of tumours","volume":"58","author":"Monstad","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.lpm.2026.104341_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1681765","article-title":"Baseline neuronal antibodies in patients with small cell lung cancer are not necessarily associated with post-immune checkpoint inhibitors neurotoxicities","volume":"16","author":"Rossi","year":"2025","journal-title":"Front Immunol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498226000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498226000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:07:56Z","timestamp":1779923276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498226000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0755498226000072"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2026.104341","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated review","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2026.104341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104341"}}